Curium to amass Lantheus in all-cash deal price as much as $8bn

CapVest Companions-backed Curium has agreed to purchase rival US-based radiopharmaceutical firm Lantheus in an all-cash deal price as much as practically $8bn.

The deal will take the Nasdaq-listed Lantheus non-public.

Underneath the settlement, Curium US will buy all excellent shares of Lantheus for $102.50 per share upon closing.

Lantheus’ shareholders are additionally set to obtain non-transferable contingent worth rights (CVRs) that would present as much as an extra $12.00 per share if sure business milestones for the corporate’s product portfolio are met by 2030. This brings the potential whole consideration per share to $114.50.

The provide represents a 38% premium to Lantheus’ 60-day volume-weighted common worth, a 29% premium to its 30-day common. It’s also 21% above the corporate’s closing worth as of 21 Might 2026, the final day earlier than media reviews emerged in regards to the potential sale.

The proposed transaction has obtained unanimous approval from Lantheus’ Board of Administrators.

Lantheus government chair and CEO Mary Anne Heino mentioned: “We consider this transaction is the final word validation of what the Lantheus staff has constructed over seven many years of innovation in radiopharmaceuticals.

“Combining strategically with Curium brings collectively two pioneers with complementary strengths and a shared ardour for nuclear medication. Collectively, we will broaden and speed up affected person entry to life-changing diagnostics and therapeutics and absolutely realise the differentiated outcomes and worth radiopharmaceuticals can ship.”

If accepted and finalised, the brand new mixed entity would function throughout oncology, neurology, and cardiology in additional than 70 nations. It should combine Curium’s theranostics capabilities and world manufacturing operations with Lantheus’ US-based radiodiagnostics enterprise.

Curium CEO Renaud Dehareng mentioned: “Lantheus is the best associate to speed up what we now have been constructing at Curium. We’ve got executed a technique to construct an revolutionary, theragnostic platform by increasing our world manufacturing footprint, advancing our radioligand remedy pipeline throughout key areas, and positioning Curium to drive the subsequent era of theragnostic innovation.

“Lantheus’ complementary enterprise accelerates our technique with a sturdy US business infrastructure, a complementary F18-isotope based mostly prostate diagnostics franchise and marks our entry within the US marketplace for diagnostic options focusing on Neurology and Echocardiography.

“Collectively, we are going to present significant theragnostic choices to sufferers from SPECT and PET diagnostics to focused radioligand remedy throughout the globe. This mix unlocks a chance that neither firm might obtain alone, because it positions us to achieve considerably extra sufferers and clinicians globally.”

The transaction will probably be financed via a mixture of debt and fairness, with no monetary circumstances connected. The businesses anticipate the merger to shut within the first half of 2027, topic to regulatory and Lantheus’ shareholder approvals.

Till then, Lantheus will proceed to function as an unbiased, publicly listed firm.

“Curium to amass Lantheus in all-cash deal price as much as $8bn” was initially created and revealed by Pharmaceutical Expertise, a GlobalData owned model.